期刊文献+

超高效液相色谱-串联质谱法测定犬血浆中利培酮和帕潘立酮及药代动力学研究 被引量:2

Determination of Risperidone and Paliperidone in Beagle Plasma by UPLC-MS/MS and Their Pharmacokinetics Studies
下载PDF
导出
摘要 建立了超高效液相色谱-串联质谱法(UPLC-MS/MS)测定犬血浆中利培酮和帕潘立酮的浓度。血浆样品用乙腈沉淀蛋白后,用Zorbax SB-C18柱分离,以乙腈-10mmol/L乙酸铵溶液(65∶35,V/V)为流动相,在电喷雾离子源正离子模式下以多反应监测(MRM)方式进行检测。利培酮、帕潘立酮分别在0.05~30.0ng/mL和0.10~30.0ng/mL范围内线性关系良好(r^2>0.99),定量限分别为0.05ng/mL和0.10ng/mL,回收率分别为91.2%~95.1%和93.1%~97.5%。该方法精密、准确、快速,适用于临床血药浓度的监测及利培酮缓释微球药动学的研究。 A method was developed for the determination of risperidone (Ris) and paliperidone (Pal) in beagle plasma by ultra performance liquid chromatography-tandem mass spectrometry. One-step protein precipitation with acetonitrile was used to extract the analytes from the plasma, and then separated on a Zorbax SB C18 column using a mixture of acetonitrile-10 mmol/L ammonium acetate(65:35 ,V/V) as the mobile phase. Detection was performed on electrospray positive ionization mass spectrometry by muhip reaction monitoring. The assay was validated over the concentration ranges of 0.05-30.0 ng/mL for R e and 0.10-30.0 ng/mL for Pal with limits of quantitation of 0.05 ng/mL and 0.10 ng/mL,and the recoveries were 91. 2%-95. 1% and 93. 1%-97. 5%, respectively. The method, which offers advantages of specificity, speed, and sensitivity is proved to be suitable for clinical investigation of risperridon microsphere pharmacokinetics.
出处 《分析科学学报》 CSCD 北大核心 2017年第3期399-402,共4页 Journal of Analytical Science
关键词 超高效液相色谱-串联质谱法 利培酮 帕潘立酮 血浆 Ultra performance liquid chromatography-tandem mass spectrometry Risperidone Paliperidone Plasma
  • 相关文献

参考文献4

二级参考文献32

  • 1张清盛,王灿灿.抗精神病药的用药现状分析[J].西部医学,2006,18(4):517-518. 被引量:4
  • 2于欣,侯也之,舒良,王秀玲,李冰,刘卫红,林凯,杨顺才,宋丽华,廖安燕,谢家康,贾宏晓,张继志.利培酮治疗精神分裂症的开放性临床验证[J].中华精神科杂志,1997,30(2):79-82. 被引量:330
  • 3Singh JB. Efficacy Safety and Tolerability of Paliperidone ER in Ado- lescent Patients with Schizophrenia. Biological Psychiatry, 2010,67 (9) :218S.
  • 4Fowler JA, Bettinger TL, Argo TR. Paliperidone extended release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther,2008,30(2) :231-248.
  • 5Marino J,Caballero J. Paliperidone extended release for the treat- ment of schizophrenia. Pharmacotherapy, 2008,28 ( 10 ) : 1283- 1298.
  • 6Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Euro J Clin, 2010,66(8) :797-803.
  • 7Dremencov E,Mansani MEI, Btier P,et al. Distinct electrophysio- logical effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacolo- gy,2007,194(3) :63-72.
  • 8Turkoz CA, Bossie j, Lindenmayer P, et al. Paliperidone ER and oral risperidone in patients with schizophrenia:a comparative da- tabase analysis. BMC Psychiatry ,2011 , 11 ( 21 ) : 1332-1340.
  • 9Davidson M,Emsley R,Kramer M,et al. Efficacy,safety and early re- sponse of paliperidone extendedrelease tablets ( paliperidone ER ) : Results of a 6 week, randomized, placebocontrolled study. J Schizo- phrenia Research ,2007,93 (5) : 117-130.
  • 10Howland RH. Managing common side effects of SSRIs. J Psychos- oc Nuts Ment Health Serv,2007,45(2):15-18.

共引文献14

同被引文献15

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部